anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: To date, there are no studies investigating the safety and outcomes of facial feminization surgery (FFS) as an outpatient procedure. This is the first study of its kind analyzing the outcomes of ambulatory FFS based on a comparison of complications, post-operative emergency department or urgent care (ED/UC) visits, and readmissions between patients who underwent FFS with admission versus same-day surgery.
METHODS: A retrospective analysis was conducted on all patients who underwent FFS in a single integrated healthcare system. Patient charts were reviewed for operative details, complications, post-operative ED/UC visits, readmission, and demographic factors. Major outcomes including complications, readmissions, and ED/UC visits were compared between groups with same-day discharge and post-operative hospital admission.
RESULTS: Of 242 patients included in the study, ED/UC visits were comparable between patients discharged same-day (18.2%) and patients admitted post-operatively (21.6%, p = 0.52). Logistic regression showed no significant difference in the composite outcomes of minor complications, major complications, and readmissions (15.6% for ambulatory versus 19.3% for admission, p = 0.46). Temporary nerve palsy, infection, and hematoma were the most common post-operative complications. However, covariates of a lower face procedure and operative time were shown to have significant differences in the composite complication outcome (p = 0.04 and p = 0.045, respectively).
CONCLUSION: Ambulatory FFS is a safe practice with no associated increase in adverse outcomes including complications, ED/UC visits, and readmission when compared to post-operative admission. Adoption of same-day FFS should be considered by high-volume gender health centers to potentially benefit from increased scheduling flexibility and efficiency, increased access to care, and lower healthcare costs.
This study proposes a randomized controlled trial of the use of glucocorticoids to improve the clinical course of neonates post-cardiopulmonary bypass (CPB). The study will focus on neonates for a few reasons. Although their post-CPB clinical course is typically more severe and intensive care unit (ICU) care more prolonged than older children, their modes of morbidity are also well characterized. Further, the high level of severity itself provides a substrate for identifying the positive effects of a particular therapy. Finally, a therapy identified as beneficial has the greatest potential for benefit in this vulnerable population. The well characterized scenario of low cardiac output syndrome (LCOS) will be used as the primary endpoint, while a variety of secondary endpoints will be related to the biochemical anti-inflammatory effects of therapy, ICU care and late neurological outcome.
The B-cell lymphoma extra large (Bcl-xL/Bak) balance has been identified as an intrinsic mechanism that is critical in determining platelet lifespan (Mason, Cell 2007). There is evidence that Bcl-xL protein expression in megakaryocytes is regulated by Thrombopoietin (TPO) mediated activation of Akt pathways mediated by Jak2 and Stat 5 (possibly by Stat 3 as well). (e.g., Kozuma et. al., Journal of Thrombosis and Haemostasis). Little is known about the Bcl-xL / Bak axis in patients with ITP, or the effect of TPO-R stimulation on platelet survival in patients with ITP. The TPO effect may be a result of stimulation of thrombopoietin-receptor (TPO-R) signalling in megakaryocytes altering the packaging of Bcl-xl into platelets, or be a direct effect of platelet TPO-R stimulation as described above.
<P>PROBLEM TO BE SOLVED: To provide a technique capable of preventing a perfuming tone from changing in a perfuming cosmetic and capable of enhancing perfuming sustainability.  <P>SOLUTION: The subject perfuming cosmetic having an emulsified form contains (1) a perfume in an amount of 7-20 mass% and (2) a triglyceride of a branched fatty acid in an amount of 1-5 mass%. Glyceryl triisostearate is preferably used as the triglyceride of the branched fatty acid. The perfuming cosmetic preferably contains a nonionic surfactant having an HLB of 9-12 in an amount of 0.1-1 mass% as a surfactant. Polyoxyethylene sorbitan monooleate is preferably used as the nonionic surfactant having the HLB of 9-12.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
PURPOSE:To obtain the titled preparation comprising coated granules of a high polymer compound soluble in the stomach, by forming a specific film of coating on the surface of a core substance containing a drug. CONSTITUTION:Very small drops of volatile liquid containing both a drug (e.g. macrolide antibiotics, tetracycline antibiotics, chloropromazine hydrochloride, etc.) or the drug and a high polymer compound (e.g. polyvinyl acetal diethylaminoacetate, dimethylaminoethyl methacrylate methacrylic acid copoly mer, etc.) are dropped on a powder bed of the high polymer compound soluble in the stomach having <=60mum particle diameter, dried and simultaneously a film of coating of the high polymer compound soluble in the stomach is formed on the surface to give a flavor oral preparation having high bioioavailability from which an unpleasant smell of drug is eliminated. A solid oral preparation such as granule, fine granule, capsule agent, tablet, etc., may be cited as the dosage form. A dried syrup can be prepared especially for child use.
An mRNA delivery system and a preparation method therefor and an application thereof. The mRNA delivery system comprises a vector and mRNA loaded on the vector. The vector comprises a lipid-like nanoparticle containing a quaternary ammonium salt lipid-like molecule. The quaternary ammonium salt lipid-like molecule has a structure as shown in formula I or formula II. The mRNA delivery system is prepared by means of the following method. The method comprises: mixing the quaternary ammonium salt lipid-like molecule with an organic solvent to obtain an organic phase; mixing the organic phase with water to obtain a mixed phase; and mixing the mixed phase with an mRNA solution to obtain the mRNA delivery system. The mRNA delivery system is simple in components; the single-component or double-component vector can realize efficient and highly specific lung-targeting mRNA delivery; the stability is excellent; the biocompatibility is good; the preparation process is simplified; the stability between batches is good; and a foundation is laid for an application of mRNA drugs in treatment of lung diseases.
The first phase of the study will take place at the National MS Center Melsbroek (NMSC). All data from the EDMUS database, a single center database at the NMSC, will be exported and checked (quantity, quality) aiming to come to a well-organized MS data structure. This MS register will be completed with volume data (intracranial, spinal canal) in a subset of patients. As a substantial number of MS patients are followed over the long-term in the MS center, the investigators expect to have longitudinal data well beyond a disease duration of 10 years at least for part of the patients. Following the export and cleaning phase of the data, the investigators will come to the basic descriptive statistics. This allows us to have an overview of all data and determine the most appropriate baseline variables or covariates as well as to define the most appropriate outcome variables. Multivariable regression analysis will be used to predict the value of outcome variables based on the independent variables whose values are known. In view of the relevance of age and disease duration in the context of MS disability and progression, time-to-event analysis will be performed, with the time to reach irreversible milestones of ambulatory disability as outcome.

In case of associations, the second phase of the study will be initiated for further analysis at the AIMS research group, VUB. At the AIMS group, VUB, the potential of false positive findings will be addressed using more sophisticated approaches (splitting cohorts in exploratory and discovery cohort, or cross-fold validation).
PURPOSE:To obtain the titled preparation soluble in water to form a clear solution, and useful as a food, drug, etc., by emulsifying or solubilizing vitamin E in an aqueous phase in the presence of a saponin, and pulverizing or granulating the emulsion or solubilized product using a vehicle. CONSTITUTION:Vitamin E is emulsified or solubilized in an aqueous phase in the presence of a saponin (e.g. quillaia saponin), and the emulsion or the solubilized product is pulverized or granulated using a vehicle (e.g. monosaccharide, disaccharide, etc.) to obtain the objective vitamin E preparation. The present vitamin E preparation gives a clear solution when dissolved in waer in contrast to the conventional powdery or granular vitamin E preparation which gives only a turbid solution even at a concentration of as low as about 0.1%. A solution having excellent stability can be produced by adding a fatty acid monoglyceride together with the saponin.
Acidovorax avenae is a flagellar bacterium pathogenic to a variety of plants and crops and is also found in a patient with hematologic malignancy, fever, or septicaemia. However, the exact mechanism of infection in humans is unknown. The inventors postulated that the human immune system responds to purified flagellin ('FLA-AA') isolated from the bacterium. In the present invention, human macrophages, fibroblasts, and TLR5-overexpressing cell lines were treated with the FLA-AA to confirm the activation of pro-inflammatory signaling pathways through TLR5 and NLRC4 at a molecular level. In order to find an effective region in the FLA-AA, four peptides ('AF1 to AF4') were designed in the α-helix of N and C terminals, and the efficacy thereof was analyzed in several cell types. Peptides AF1 and AF2 showed agonistic activity through TLR1/2 and TLR4, but not through TLR5. This suggests the cross-reactivity of flagellin fragments with members of the same family of toll-like receptors. Short flagellin fragments have the potential as a therapeutic agonist or an adjuvant in cancer immunotherapy.
The invention belongs to the technical field of monoclonal antibodies, and particularly discloses a humanized ALR human mouse chimeric monoclonal antibody, wherein a heavy chain variable region comprises three CDRs (complementary deoxyribonucleic acid) regions, and amino acid sequences of the three CDRs are respectively SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5; the light chain variable region comprises three CDRs, and the amino acid sequences are SEQ ID NO 6, SEQ ID NO 7 and SEQ ID NO 8 respectively. The invention also discloses application of the humanized ALR human mouse chimeric monoclonal antibody in treatment of liver cancer and multiple myeloma. The humanized ALR human mouse chimeric monoclonal antibody disclosed by the invention lays a foundation for further researching the action of hALR in the occurrence and development processes of liver cancer and multiple myeloma in the future.
This review provides an overview of the treatment options available for gastric varices (GV) with a focus on endoscopic methods. Various minimally invasive techniques, including endoscopic band ligation, endoscopic cyanoacrylate injection, and transjugular intrahepatic portosystemic shunt, can be applied to the treatment of GV. Endoscopic cyanoacrylate injection is now recognized as a first-line treatment for GV. Endoscopic ultrasound-guided cyanoacrylate injection combined with coils has shown good security and effectiveness. Thrombin injection therapy is a promising treatment, with a similar hemostasis rate to cyanoacrylate injection but with fewer serious complications. With the deepening understanding of the hemodynamics of the GV system, various treatment methods and their combination are gradually evaluated to provide patients with safer and more effective treatment options.
Cold compression application was performed using Game Ready for 15 minutes. The target temperature was manually set to 10°C and the pressure to high compression (75 mm Hg). Pneumatic intermittent compression in a standard ∼3 min cycle was applied to both lower legs using a thigh wrap. The application was performed with the athletes in the supine semi-recumbent position.
While balanced reciprocal translocations are relatively common, they often remain clinically silent unless they lead to the disruption of functional genes. In this study, we present the case of a boy exhibiting developmental delay and mild intellectual disability. Initial karyotyping revealed a translocation t(5;6)(q13;q23) between chromosomes 5 and 6 with limited resolution. Optical genome mapping (OGM) enabled a more precise depiction of the breakpoint regions involved in the reciprocal translocation. While the breakpoint region on chromosome 6 did not encompass any known gene, OGM revealed the disruption of the RASGRF2 (Ras protein-specific guanine nucleotide releasing factor 2) gene on chromosome 5, implicating RASGRF2 as a potential candidate gene contributing to the observed developmental delay in the patient. Variations in RASGRF2 have so far not been reported in developmental delay, but research on the RASGRF2 gene underscores its significance in various aspects of neurodevelopment, including synaptic plasticity, signaling pathways, and behavioral responses. This study highlights the utility of OGM in identifying breakpoint regions, providing possible insights into the understanding of neurodevelopmental disorders. It also helps affected individuals in gaining more knowledge about potential causes of their conditions.
Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
OBJECTIVES: I. Evaluate the 1 and 2 year event free survival of patients with poor prognosis, relapsed or refractory intermediate or high grade B-cell non-Hodgkin's lymphoma who receive high dose carmustine and melphalan plus gemcitabine followed by rituximab (IDEC-C2B8 monoclonal antibody; anti-CD20 monoclonal antibody) plus sargramostim and consolidation chemotherapy with alternating dexamethasone/cyclophosphamide/ etoposide/cisplatin plus gemcitabine and paclitaxel/cisplatin and compare these figures to a historical control population. II. Evaluate the ability of posttransplant rituximab therapy in combination with sargramostim (GM-CSF) to control and further treat residual lymphoma remaining after high dose therapy in these patients. III. Evaluate quality of life parameters and assess the risk of secondary malignancies following this treatment regimen in these patients.

OUTLINE: Patients receive high dose gemcitabine IV over 100 minutes on day -5 and again approximately 6 hours after carmustine IV over 2 hours on day -2. On day -1, patients receive melphalan IV over 20 minutes followed 24 hours later (day 0) with peripheral blood stem cells transplantation. Patients then receive sargramostim (GM-CSF) subcutaneously beginning on day 4 until granulocyte count is greater than 1,000/mm3 for 2 consecutive days. At weeks 5-8 posttransplant, patients receive rituximab (IDEC-C2B8 monoclonal antibody; anti-CD20 monoclonal antibody) IV over 3-4 hours weekly. Prior to rituximab treatment at week 4 posttransplant, patients receive sargramostim (GM-CSF) subcutaneously 3 times a week continuing through rituximab therapy. At approximately 3 and 9 months posttransplant, patients receive dexamethasone orally every day for days 1-4, and cyclophosphamide, etoposide, and cisplatin by continuous infusion for 4 days (days 1-4), and gemcitabine IV over 100 minutes on days 1 and 5. At approximately 6 and 12 months posttransplant, patients receive paclitaxel IV over 6 hours on day 2 and cisplatin IV over 24 hours on day 3. Patients are followed at least every 6 weeks to 3 months until death.

PROJECTED ACCRUAL: An estimated 25 patients per year will be accrued into this study.
A server is programmed to predict high burden behavioral health insurance plan participants. The server receives health data from several data sources. The data is associated with the insurance plan participants. The server develops data variables and risk metrics relating to behavioral health of the participants. Sample data is collected from the health data. The sample data includes a first sample data set including a plurality of first values relating to the plurality of data variables, and a second sample data set including a plurality of second values relating to the plurality of risk metrics. The server analyzes the first and second sample data sets to determine one or more correlations between the first values and the second values. The server configures a software model to implement the correlations to predict which of the participants are at risk of becoming burden behavioral health insurance plan participants.
This arm includes 9 professionals (including medical staff, child development specialists, and psychologists). All participants will use the mindfulness-based serious game designed for pain management and will complete usability surveys and participate in interviews to provide feedback on their experience.
Low back pain (LBP) is one of the most common and costly musculoskeletal conditions impacting health care in the United States. The development of multimodal strategies of treatment is imperative in order to curb the growing incidence and prevalence of LBP. Spinal manipulative therapy (SMT), dry needling (DN), and exercise are common nonpharmacological treatments for LBP. This study is a 3-armed parallel-group design randomized clinical trial. We enrolled and randomized 96 participants with LBP into a multimodal strategy of treatment consisting of a combination of DN and SMT, DN only, and SMT only, followed by an at-home exercise program. All participants received 4 treatment sessions in the first 2 weeks followed by a 2-week home exercise program. Outcomes included clinical (Oswestry Disability Index, numeric pain intensity rating) and mechanistic (lumbar multifidus, erector spinae, and gluteus medius muscle activation) measures at baseline, 2, and 4 weeks. Participants in the DN and SMT groups showed larger effects and statistically significant improvement in pain and disability scores, and muscle percent thickness change at 2 weeks and 4 weeks of treatment when compared to the other groups. This study was registered prior to participant enrollment. PERSPECTIVE: This article presents the process of developing an optimized multimodal treatment plan utilizing SMT, DN, and exercise to address the burden of LBP for impacted individuals and the health care system. This method could potentially help clinicians who treat LBP to lower initial pain and increase exercise compliance. (clinicaltrials.gov NCT05802901).
A conjugate comprising interleukin-4 (IL4) and a specific binding member is disclosed. The specific binding member preferably binds an extra-cellular matrix component associated with neoplastic growth and/or angiogenesis, and the conjugate may be used for targeting IL4 to tissues in vivo. In particular, the therapeutic use of such conjugates in the treatment of a disease/disorder, such as cancer and/or autoimmune diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS), endometriosis, inflammatory bowel disease (IBD), psoriasis, psoriatic arthritis, and periodontitis is envisaged. Other diseases which may be treated or prevented using the conjugates include autoimmune insulitis and diabetes, in particular autoimmune diabetes. In the treatment of cancer, the conjugate may be administered in combination with a conjugate comprising either interleukin-12 (IL12) or interleukin-2 (IL2) and a specific binding member. In the treatment of autoimmune diseases, the conjugate may be administered in combination with a glucocorticoid, such as dexamethasone.
BACKGROUND: The perioperative antibiotic prophylaxis with 1st or 2nd generation cephalosporins is evidence-based in orthopedic surgery. There are, however, situations with a high risk of prophylaxis-resistant surgical site infections (SSI).
METHODS: We perform a superiority randomized controlled trial with a 10% margin and a power of 90% in favor of the broad-spectrum prophylaxis. We will randomize orthopedic interventions with a high risk for SSI due to selection of resistant pathogens (open fractures, surgery under therapeutic antibiotics, orthopedic tumor surgery, spine surgery with American Society of Anesthesiologists (ASA) score ≥ 3 points) in a prospective-alternating scheme (1:1, standard prophylaxis with cefuroxime versus a broad-spectrum prophylaxis of a combined single-shot of vancomycin 1 g and gentamicin 5 mg/kg parenterally). The primary outcome is "remission" at 6 weeks for most orthopedic surgeries or at 1 year for surgeries with implant. Secondary outcomes are the risk for prophylaxis-resistant SSI pathogens, revision surgery for any reason, change of antibiotic therapy during the treatment of infection, adverse events, and the postoperative healthcare-associated infections other than SSI within 6 weeks (e.g., urine infections or pneumonia). With event-free surgeries to 95% in the broad-spectrum versus 85% in the standard prophylaxis arm, we need 2 × 207 orthopedic surgeries.
DISCUSSION: In selected patients with a high risk for infections due to selection of prophylaxis-resistant SSI, a broad-spectrum combination with vancomycin and gentamycin might prevent SSIs (and other postoperative infections) better than the prophylaxis with cefuroxime.
TRIAL REGISTRATION: ClinicalTrial.gov NCT05502380. Registered on 12 August 2022. Protocol version: 2 (3 June 2022).
The invention discloses a type of traditional Chinese medicine external medicinal liquor used for treating seborrheic dermatitis. The medicinal liquor is characterized in that: the medicinal liquor is prepared from the raw medicines of, by weight: 1.3 to 1.5 parts of sulfur, 0.3 to 0.5 parts of calomeas, 0.3 to 0.5 parts of dried alum, and 0.117 to 0.125 parts of borneol; the raw medicines are processed into a powder, and the powder is added to and immersed in 80 to 100 parts of alcohol. The traditional Chinese medicine external medicinal liquor used for treating seborrheic dermatitis brings effects of detoxifying, insect disinfesting, dampness dissolving, and itching relieving. The medicinal liquor is safe, and brings no side effect to human bodies. The medicinal liquor does not cause skin allergy, and does not hurt skins. The medicinal liquor brings a substantial curing effect upon seborrheic dermatitis. With the medicinal liquor, seborrheic dermatitis is not easy to reoccur.